Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time ...

Several companies rightfully used the heavily sought-after screen time to raise awareness and send powerful messages, and it ...

Direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention side effects of the drugs.

After a telehealth company's Super Bowl commercial sparked nationwide debate about pharmaceutical safety and advertising, one DSO executive is reflecting on what the controversy means for patient care ...

Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

AJ Toler was taken aback by Hims’ scathing criticism of obesity in their weight-loss drug Super Bowl commercial.

By: Katie Karlson and Madeline Darby Super Bowl commercials have been a cultural phenomenon for years. However, this year, one commercial sparked widespread controversy and a heated debate about the ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...